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Abstract
In hemostasis, the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1)
functions to stabilize clots via inhibition of tissue plasminogen activator (tPA) with subsequent
inhibition of fibrinolysis. In tissues, PAI-1 functions to inhibit extracellular matrix degradation via
inhibition of urokinase plasminogen activator (uPA). Elevated levels of PAI-1 in the vasculature
and in tissues have long been known to be associated with thrombosis and fibrosis, respectively.
However, there is emerging evidence that PAI-1 may participate in the pathophysiology of a
number of diseases such as atherosclerosis, restenosis, and cancer. In many of these disease states,
the canonical view of PAI-1 as an inhibitor of tPA and uPA cannot fully account for a mechanism
whereby PAI-1 contributes to the disease. In these cases, one must consider recent data, which
indicates PAI-1 can directly promote pro-proliferative and anti-apoptotic signaling in a variety of
cell types. Given the wide variety of inflammatory, hormonal, and metabolic signals that increase
PAI-1 expression, it is important to consider mechanisms by which PAI-1 can directly participate
in disease etiology.
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Traditional paradigms for PAI-1 in fibrinolysis and tissue remodeling
Within the intravascular space, the primary role for the serpin (serine protease inhibitor)
PAI-1 is to regulate fibrinolysis to stabilize hemostatic plug formation. When bound to
fibrin in a clot, the serine protease tissue plasminogen activator (tPA) activates plasminogen
to its active form of plasmin, which subsequently degrades fibrin [1]. During thrombus
formation, tPA is inhibited by PAI-1 released from platelets [2], thereby limiting further
plasminogen activation and fibrinolysis.
The primary role of PAI-1 in the extravascular space is to regulate matrix remodeling via
inhibition of the urokinase plasminogen activator (uPA) [3]. uPA bound to cells expressing
its cognate receptor uPAR, can catalyze the pericellular conversion of plasminogen to
plasmin, which can subsequently cleave and/or activate numerous proteins such as
gelatinase, fibronectin, laminin, and latent forms of collagenases including MMP-1 to lead
to matrix degradation. As with tPA, PAI-1 forms a 1:1 complex with uPA and renders the
protease inactive, thereby inhibiting pericellular proteolysis.
PAI-1 has also been implicated in inhibiting adhesion of cells to extracellular matrix
proteins, although the precise mechanism remains debated. uPAR has been shown to
associate with multiple different integrin subunits and it has been suggested that uPAR can
act as an integrin ligand to promote both cell adhesion to various matrix proteins [4], as well
as cell to cell adhesion [5]. Given these findings, it has been suggested that PAI-1 may
promote de-adhesion from various substrata via destruction of integrins [6]. Alternatively, is
has been suggested that PAI-1 can promote de-adhesion specifically for the extracellular
matrix protein vitronectin (VN). PAI-1 and uPAR/uPA complexes compete for binding to
VN [7], and binding of PAI-1 to uPA dissociates uPAR from vitronectin. Endocytosis of the
uPAR/uPA/PAI-1 ternary complex by the low-density lipoprotein-like receptor 1 (LRP-1)
then promotes de-adhesion of cells from VN [8].
Regulation of PAI-1 expression in the intravascular and extravascular space
During the initiation of thrombus formation, release of PAI-1 by platelets represents the
most likely primary source of PAI-1 [2]. However, multiple cell types are capable of
producing PAI-1 in response to various inflammatory cytokines. The multiplicity of
potential sources of PAI-1 as a response factor has implications for PAI-1 function in both
physiological and pathophysiological conditions.
As a recognized acute phase reactant, PAI-1 levels in plasma increase quickly in response to
vessel injury and a heightened inflammatory state [9]. Like C-reactive protein (CRP) and
fibrinogen, PAI-1 levels in plasma have been shown to increase in response both to acute
trauma such as local tissue injury [10] and to chronic inflammatory states such as
cardiovascular disease [11] and insulin resistance [12]. In mouse models, this increase has
been attributed to increased synthesis of PAI-1 by the liver in response to inflammatory
cytokines IL-1β [10], IL-6 [13], and tumor necrosis factor-α (TNFα) [14]. Under
physiological conditions, acute increases in the plasma concentration of PAI-1 in response to
inflammatory cytokines could be viewed as a mechanism to stabilize thrombus formation by
inhibiting tPA-mediated plasminogen activation. However, under pathological conditions
such as atherosclerosis, sustained elevated levels of PAI-1 could promote thrombosis.
In contrast to fast up-regulation of PAI-1 in plasma as an acute phase reactant, there are also
mechanisms by which PAI-1 levels in the intravascular space may be up-regulated in a more
sustained fashion via endothelial cell production. Similar to hepatocytes, cultured
endothelial cells have been shown to increase PAI-1 production in response to the
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inflammatory cytokines IL-1 [15] and TNF-α [16]. PAI-1 synthesis by endothelial cells has
also been shown to increase as a consequence of hypoxia [17], the generation of reactive
oxygen species [18], and shear stress [19]. Alternatively, increased PAI-1 production by
endothelial cells has also been associated with senescence, a process that increases with age
[20].
Extravascularly, regulation of PAI-1 expression involves multiple cell types. In fibroblasts,
PAI-1 synthesis is increased in response to TGF-β [21] and IL-6 [22]. Perhaps the most
important source of PAI-1 in tissues is adipocytes. Mature adipocytes express relatively high
basal levels of PAI-I in culture [23]. Despite high basal expression, adipocytes can increase
PAI-1 synthesis in response to many cytokines and hormones such as TNF-α, TGF-β, and
insulin [24]. Finally, macrophages represent another source of PAI-1 in the extravascular
space. Activation of monocytes with endotoxin increases PAI-1 expression and histological
studies indicate that tissue macrophages in artheromatous plaques express PAI-1 [25].
Given the diversity of cellular sources and multitude of inflammatory signals which promote
PAI-1 expression, it is not surprising that elevated PAI-1 levels in serum and tissue have
been observed in a variety of pathological conditions. One might suggest elevated PAI-1
levels could be merely a marker of inflammation. However, multiple studies have shown
that PAI-1 participates directly in the pathophysiology of a number of diseases. In some
cases, the traditional paradigms for the function of PAI-1 can fully explain its role in
pathology. Alternatively, in other disease states, the traditional paradigms for the function of
PAI-1 are not sufficient to understand its participatory role. Thus, new data are emerging
that strongly suggests PAI-1 has novel functions far beyond its ability to inhibit tPA and
uPA.
Pathologic consequences of PAI-1 expression explained by traditional
paradigms
PAI-1 in thrombosis
As an inhibitor of plasminogen activation and fibrin degradation, it is logical that elevated
PAI-1 levels in serum would lead to thrombosis. With regard for thrombosis in the coronary
arteries, elevated PAI-1 levels have been documented in the serum of survivors of a
myocardial infarction and patients that have recurrent myocardial infarctions [26]. In an
experimental model, transgenic mice that express a stable form of human PAI-1 develop
spontaneous coronary thrombi [27]. Elevated levels of PAI-1, especially in the elderly, are
thought to be associated with both venous and arterial thrombosis [28].
PAI-1 in fibrosis
In tissues, increased expression of PAI-1 has been associated with multiple forms of fibrosis
including glomerulosclerosis [29], liver fibrosis [30], and pulmonary fibrosis [31]. While
there are competing schools of thought on the role of PAI-1 in promoting fibrosis, all utilize
the traditional paradigm for PAI-1 function. First, it is thought that elevated PAI-1
expression decreases tPA/uPA activity leading to increased fibrin deposition at the site of a
vessel injury. Due to the increased fibrin deposition, more cells infiltrate the wound, leading
to increased collagen deposition. In an alternative model, it has been suggested elevated
PAI-1 promotes de-adhesion, allowing for more cells to infiltrate. Finally, it has also been
suggested that the primary consequence of elevated PAI-1 is actually decreased collagenase
activity downstream of reduced uPA and MMP activation. In this model PAI-1 directly
promotes fibrosis by inhibiting collagen degradation [32].
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In contrast to observations linking PAI-1 to thrombosis and fibrotic disease, the role of
PAI-1 in other pathological conditions are not explained by traditional paradigms, which
focus solely on the protease inhibitor activity of PAI-1. More recent studies elucidating the
ability of PAI-1 to alter cell signaling is providing insight to explain how PAI-1 can
contribute to other disease states.
Pathologic consequences of PAI-1 expression not explained by traditional
paradigms
PAI-1 in vascular disease
PAI-1 has a well-documented association with the development of vascular disease.
Multiple studies have demonstrated the presence of excess PAI-1 in atherosclerotic plaques
[33] [34] [25]. Furthermore, PAI-1 deposition in the vascular wall [35], and atherosclerotic
plaques [36], is elevated in patients with type II diabetes. This is not surprising given that
elevated PAI-1 expression has been directly linked to hyperinsulinemia as well as glucose/
lipid imbalance [37].
It has been suggested that the presence of PAI-1 in atherosclerotic plaques may directly
contribute to atherogenesis primarily via inhibition of MMP activation with subsequent
decreased activation of TGFβ [38], which promotes smooth muscle cell proliferation, and
decreased processing of cholesterol aggregates [26]. However, there are other mechanisms
by which PAI-1 may promote the development of atherosclerosis that reach beyond the
traditional paradigms of tPA/uPA inhibition. Of note, PAI-1 has shown to directly promote
migration, inhibit apoptosis [39], and promote proliferation [40] of smooth muscle cells.
These studies elucidate that PAI-1 has unique capabilities to promote cell signaling. With
regard to apoptosis and proliferation, these studies show purified PAI-1 inhibits caspase-3
activity in vitro [39], and promotes cell proliferation via activation of the NFκB and ERK
signaling [40]. Given the importance of smooth muscle cell proliferation in the development
of atherosclerotic lesions, it is important to consider the potential role of PAI-1 directly
mediating intracellular signaling events in vascular disease.
Another interesting potential mechanism of PAI-1 mediated signaling in vascular disease
involves macrophages recruitment. In in vitro studies, PAI-1 in combination with tPA and
LRP-1 (the co-receptor for clearance of tPA-PAI-1 and uPA-PAI-1 complexes), has been
shown coordinate Mac-1 dependent macrophage migration [41]. While the authors of these
studies suggest PAI-1 mediated migration of macrophages is a function of the de-adhesive
functions of PAI-1, it is likely to involve more complicated signaling events in light of data
which shows the LRP-1 co-receptor acts as a motogenic receptor for PAI-1, and can activate
Jak/Stat signaling when it binds PAI-1 [42].
PAI-1 in the tumor microenvironment
The tumor microenvironment represents a heterogeneous mixture of cell types, many of
which can produce and respond to PAI-1, including the tumor cells themselves. Considering
the well documented role of the immune system and inflammation in cancer and the tight
linkage between inflammation and elevated PAI-1, one might hypothesize that PAI-1 could
play a direct role in the pathophysiology of cancer. This hypothesis should garner close
investigation given that elevated PAI-1 levels in the tumor microenvironment correlates to
poor prognosis in multiple cancers including breast [43], ovarian [44], pulmonary
adenocarcinoma [45], and neuroblastoma [46]. The commonly observed elevation of PAI-1
in cancer presents a difficult paradox. Given the well-documented association of matrix
degradation with tumor viability and metastasis, one would expect that PAI-1, as an
inhibitor of uPA, would represent a positive prognostic indicator. However, insights into the
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novel functions of PAI-1 as a cell signaling mediator may help explain why PAI-1 is often a
poor prognostic indicator.
Most directly, PAI-1 produced by adipocytes, fibroblasts, or macrophages in response to
various cytokines in the tumor microenvironment can promote angiogenesis, which is
crucial to tumor viability and dissemination. While not without controversy, PAI-1 is
generally accepted to promote angiogenesis in the tumor microenvironment. Utilizing
PAI-1−/− mice, it has been shown PAI-1 promotes angiogenesis in the tumor
microenvironment at low concentrations but inhibits angiogenesis at extremely high
concentrations [47]. The precise mechanism by which PAI-1 promotes angiogenesis has
remained largely elusive, although it has been suggested that the ability of PAI-1 to promote
angiogenesis is dependent on it protease inhibitor activity, not vitronectin binding [48]. This
finding would suggest PAI-1 does not promote angiogenesis by promoting de-adhesion of
endothelial cells from matrix proteins. The most complete study analyzing angiogenesis
suggests that PAI-1 inhibits pro-apoptotic cell signaling by inhibiting plasmin mediated
cleavage of Fas-ligand on the surface of endothelial cells [49]. This represents a novel
mechanism for how PAI-1 prevents apoptosis of endothelial cells and therefore promotes
angiogenesis.
Another mechanism whereby PAI-1 could function to promote cancer dissemination comes
from a novel finding with senescence in fibroblasts. PAI-1 has long been known as a marker
of senescence in multiple cell types [50] [51]. However, it has been shown that PAI-1 is not
only a marker of senescence in fibroblasts, but that it is a critical downstream target of p53
in the induction of senescence, through a PI3K-dependent pathway [52]. If PAI-1 can
participate directly in the induction of replicative senescence, it is possible that an excess of
PAI-1 in the tumor microenvironment could induce the senescence of fibroblasts, leading to
decreased deposition of matrix.
Outside of its influence on endothelial cells and fibroblasts in the tumor microenvironment,
emerging data suggests PAI-1 has direct influence over pro-proliferative and anti-apoptotic
signaling in tumor cells themselves. While mouse models designed to examine the effect of
PAI-1 on tumor development have yielded often-conflicting data [53], in vitro examination
of various cancer cell lines indicates that PAI-1 has a positive influence on cancer cell
growth and survival. While limited, this data may provide the most direct link to explain
why elevated PAI-1 levels are associated with poor prognosis in cancer.
One such study demonstrated that both the PC-3 prostate cancer cell line and the HL-60
promyelocytic cell line demonstrated decreased apoptosis in the presence of PAI-1 when
treated with apoptosis inducing agents camptothecin or etoposide [54]. Similarly, our
laboratory has found that stable expression of wild type PAI-1, but not an inactive mutant of
PAI-1, enhances the recovery of MDA-MB-435 cancer cells after exposure to apoptosis
inducing agent paclitaxel [55], and enhances motility and adhesion via alteration of the
integrin profile at the cell surface [56]. Fibrosarcoma cell lines derived from PAI-1−/− mice
were significantly more sensitive to apoptotic stimulus etoposide than counterpart
fibrosarcoma cell lines from wild type mice [57].
More recent data reveals how PAI-1 may influence cancer cell viability via direct alteration
of cell signaling. An expanded analysis of the murine fibrosarcoma cells discussed above
revealed that PAI-1 deficient fibrosarcomas have reduced Akt signaling and reintroduction
of PAI-1 expression in deficient cells results in an increase in Akt signaling [58]. Our
laboratory has found that stable knockdown of PAI-1 expression in MDA-MB-231 breast
cancer cells results in decreased Akt activation (Gramling, M.W. and F.C. Church,
unpublished data). Besides regulation of anti-apoptotic Akt signaling, PAI-1 has also been
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shown to activate pro-proliferative MAPK signaling. In MCF-7 breast cancer cells, PAI-1
promotes sustained phosphorylation of ERK1/2 via a mechanism which is dependent on its
interaction with uPA as well as the activity of uPAR and the LRP-1 co-receptor [59]. This
study further showed that the presence of PAI-1 allowed uPA to act as a mitogen for the
breast cancer cells [59].
Conclusion
Given that PAI-1 expression is elevated both the intra- and extra-vascular space by such a
wide variety of inflammatory, hormonal, and metabolic signals, it has potential to influence
many physiological and pathophysiological conditions. The pleiotropic effects of PAI-1 are
diagrammed in Figure 1. From thrombosis and fibrosis to atherosclerosis and cancer, PAI-1
directly contributes to the etiology of disease via mechanisms explained by traditional
paradigms of its function and by new mechanisms explained by its emerging role in altering
cell signaling.
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PAI-1 has been implicated in modulating a variety of physiological and pathophysiological
processes. PAI-1 expression in the intra- and extra-vascular space is increased in response to
many inflammatory, hormonal, and metabolic signals. By modulating protease activity,
adhesion, and altering signaling in multiple cell types, PAI-1 can contribute to many normal
and disease processes.
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